By proceeding, you agree to our Terms of Use and Privacy Policy.
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.
16-18 March 2022
IO360°convenes stakeholders from the science and business communities to report on the latest data impacting IO to fight a wider range of cancers.
Event Ended
USA
Paid
New York